DEPAKIN 150ML SYRUP

Indications

Approved Uses

Epilepsy/seizure disorders (including generalized and focal/partial seizures, and absence seizures; as monotherapy or adjunctive therapy depending on seizure type and patient factors).

Off-Label Uses

Off-label uses vary by jurisdiction; commonly cited off-label uses include agitation/aggression in certain neuropsychiatric conditions and some pain syndromes (e.g., neuropathic pain), but evidence is mixed and these are not SFDA-verified indications for this product.

Dosage & Administration

Dosing by Condition

Epilepsy (adults): Initial 10-15 mg/kg/day in divided doses, increase by 5-10 mg/kg/week; maintenance generally <60 mg/kg/day. No FDA dosing for bipolar mania or migraine prophylaxis in Depakene label.

Initial Dose

Adults (epilepsy): 10-15 mg/kg/day PO in 2-3 divided doses; increase by 5-10 mg/kg/day at weekly intervals as needed/tolerated. Bipolar mania: 750 mg/day PO in divided doses (or 20 mg/kg/day), then adjust based on clinical response and serum levels.

Maintenance Dose

Epilepsy (adults): typically 15-60 mg/kg/day PO in divided doses (commonly ~1000-2500 mg/day; max 60 mg/kg/day), adjusted to clinical response and serum valproate concentrations.

Maximum Dose

60 mg/kg/day (adults and children); 3000 mg/day for migraine prophylaxis

Children's Dosage

Children ≥2 years: 15-45 mg/kg/day in divided doses; start at 15 mg/kg/day and increase by 5-10 mg/kg/week; use with extreme caution in children under 2 years due to high risk of fatal hepatotoxicity

Dose Adjustment Notes

Start low and titrate gradually to clinical response and tolerability; use therapeutic drug monitoring when clinically indicated (e.g., lack of response, suspected toxicity, interactions, adherence issues); reduce starting dose and titrate more slowly in the elderly; avoid/use extreme caution in hepatic impairment (contraindicated in significant liver disease); in renal impairment, total levels may be misleading-monitor clinical response and consider free valproate if hypoalbuminemia/renal dysfunction; divide doses for immediate-release syrup as prescribed.

How to Take

Shake well before each dose; administer orally using the provided measuring device (not a household spoon); may be taken with or without food-taking with food can reduce gastrointestinal upset; take at the same times daily and divide the total daily dose as prescribed (often 2-3 divided doses for immediate-release liquid formulations).

Side Effects

Common Side Effects

Nausea, vomiting, diarrhea, abdominal pain, weight gain, tremor, somnolence, dizziness, headache, alopecia (hair loss), thrombocytopenia, increased appetite

Side Effect Frequency

Very common/common adverse effects include GI upset (nausea ± vomiting), tremor, somnolence, weight gain/increased appetite, and alopecia; thrombocytopenia is a recognized common/very common dose-related effect; serious but rare risks include hepatotoxicity, pancreatitis, severe cutaneous reactions (e.g., SJS/TEN), and hyperammonemic encephalopathy.

Safety & Warnings

Contraindications

Contraindicated in: active liver disease/significant hepatic dysfunction; known mitochondrial disorders caused by POLG mutations (and children <2 years suspected of POLG-related disease); known urea cycle disorders; hypersensitivity to valproate/valproic acid/valproate sodium; porphyria. Also contraindicated for migraine prophylaxis in pregnancy (and in women of childbearing potential not using effective contraception, per many regulators).

Warnings & Precautions

Key warnings/precautions: monitor for hepatotoxicity (baseline and during first 6 months; highest risk in children <2 years and POLG/metabolic disorders); pancreatitis (stop if suspected); strong pregnancy prevention/avoidance due to teratogenicity and neurodevelopmental risk; hyperammonemia/encephalopathy risk (especially with urea cycle disorders or topiramate); thrombocytopenia/bleeding (monitor platelets/coagulation as indicated); suicidality monitoring; avoid/use extreme caution in mitochondrial (POLG) disease; counsel on CNS effects, weight gain/metabolic effects, and endocrine effects (e.g., menstrual irregularities/possible PCOS).

Age Restriction

Not contraindicated by age, but use with extreme caution in children <2 years (highest risk of fatal hepatotoxicity), especially with polytherapy or suspected metabolic/mitochondrial disorders; may be used in children ≥2 years when clinically indicated for epilepsy under specialist supervision.

Driving Warning

May Cause Drowsiness

Drug Interactions

Drug Interactions

Clinically important interactions include: carbapenems (markedly decrease valproate concentrations-avoid if possible); lamotrigine (valproate increases lamotrigine levels/SJS risk-use lower lamotrigine doses); phenobarbital (valproate increases levels/CNS depression); phenytoin (protein-binding/metabolism interaction-monitor free levels); topiramate (increased risk of hyperammonemia/encephalopathy); aspirin/salicylates (increase free valproate/bleeding risk, especially in children); warfarin/other anticoagulants (increased bleeding via protein-binding/platelet effects-monitor INR/bleeding); alcohol/other CNS depressants (additive sedation).

Special Populations

Pregnancy

Contraindicated

Breastfeeding

Caution

Children

Children ≥2 years: 15-45 mg/kg/day in divided doses; start at 15 mg/kg/day and increase by 5-10 mg/kg/week; use with extreme caution in children under 2 years due to high risk of fatal hepatotoxicity

Elderly

Start at lower doses and titrate slowly; monitor for excessive sedation, tremor, and fluid/nutritional intake; lower protein binding in elderly may increase free drug levels

Liver Impairment

Contraindicated in significant hepatic impairment/active liver disease; if mild impairment is present, use only if benefits outweigh risks with specialist oversight, consider lower starting dose and close clinical/LFT monitoring.

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule; do not double doses.

Stopping the Medicine

Do not stop abruptly; taper gradually under medical supervision to reduce risk of seizure recurrence/status epilepticus.

Overdose

Overdose may cause CNS depression (drowsiness to coma), respiratory depression, hypotension, metabolic acidosis, hyperammonemia, and rarely cerebral edema; management is urgent supportive care (airway/ventilation, hemodynamics), activated charcoal if appropriate, consider L-carnitine for significant toxicity/hyperammonemia/hepatotoxicity, and hemodialysis in severe poisoning (very high levels, shock, severe acidosis, cerebral edema).

Patient Counseling

Key counseling: take exactly as prescribed and do not stop abruptly; shake well and measure doses accurately; may take with food to reduce stomach upset; avoid alcohol and use caution with driving until effects are known; urgently report signs of liver injury (jaundice, dark urine, severe fatigue), pancreatitis (severe abdominal pain), unusual bruising/bleeding, or marked drowsiness/confusion (possible hyperammonemia); discuss all new medicines due to major interactions (especially carbapenems and lamotrigine); pregnancy prevention is critical-valproate is highly teratogenic and generally should be avoided in pregnancy unless no suitable alternative, with effective contraception and specialist oversight.

Monitoring Requirements

Baseline and periodic: liver function tests (especially during the first 6 months), complete blood count including platelets; consider coagulation parameters (e.g., PT/INR) if bleeding risk/surgery; serum valproate concentrations when clinically indicated; monitor weight/metabolic effects; check ammonia if unexplained lethargy/vomiting/mental status changes; assess for pancreatitis symptoms.

Pharmacology

Mechanism of Action

Increases inhibitory neurotransmission by increasing brain GABA (via effects on GABA metabolism) and also modulates neuronal firing by blocking voltage-gated sodium channels and reducing T-type calcium currents.

Duration of Effect

Immediate-release valproate syrup provides therapeutic effect for ~8-12 hours per dose (consistent with divided dosing 2-3 times daily); elimination half-life is commonly ~9-16 hours (variable with age, comedications, and hepatic function).

Half-Life

Adults: 13-19 hours; generally shorter in children (often 7-13 hours in infants <2 months, variable) and longer in neonates (10-67 hours).

Bioavailability

Oral bioavailability is high and essentially complete for immediate-release valproate (≈90-100%); extended-release products have lower relative bioavailability (~80-90% vs delayed-release).

Protein Binding

High, concentration-dependent protein binding (typically ~80-95% to albumin; decreases at higher concentrations and in hypoalbuminemia).

Product Information

Available Dosage Forms

Syrup (oral use) for this specific SFDA product; other valproate dosage forms exist globally (e.g., gastro-resistant/modified-release tablets, capsules/granules, and IV formulations) but are product- and country-specific and cannot be asserted for this SFDA-registered item without local registration evidence.

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Also Used For

Mood Stabilization, Migraine Prevention, Neuropathic Pain, Bipolar Disorder

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.